Evidence map›Paper›PMID 40517368›Full record

ArticleClinical physiology and functional imaging2025

Evaluation of [18F]PSMA-1007 uptake variability in patients with prostate cancer.

Elin Trägårdh, Måns Larsson, David Minarik, Olof Enqvist, Lars Edenbrandt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical physiology and functional imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elin TrägårdhDepartment of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, Sweden.ORCID https://orcid.org/0000-0002-7116-303X
Måns LarssonEigenvision AB, Malmö, Sweden.ORCID https://orcid.org/0000-0003-3137-1405
David MinarikDepartment of Translational Medicine and Wallenberg Center for Molecular Medicine, Lund University, Malmö, Sweden.ORCID https://orcid.org/0009-0000-8129-3228
Olof EnqvistEigenvision AB, Malmö, Sweden.ORCID https://orcid.org/0000-0002-7456-1009
Lars EdenbrandtInstitute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Funding

Knut and Alice Wallenberg FoundationMalmö General Hospital FoundationMedical Faculty at Lund UniversityRegion SkåneSwedish Cancer FoundationSwedish Prostate Cancer Foundation
6 · The paper itself

Abstract

backgroundThe biodistribution of PSMA-ligands is of interest in radionuclide therapy planning. We investigated the variability of [

methodsA total of 1086 patients who underwent PSMA PET-CT for staging or recurrence of prostate cancer were included. Total lesion volume (TLV) and total lesion uptake (TLU) were calculated from manual segmentations. The mean standardized uptake value (SUV

resultsThe median (IQR) SUV

conclusionsThere was a large uptake variability in organs at risk, which demonstrates the need for individual pretherapy dosimetry. There may be a tumour sink effect in the kidneys and parotid glands in patients with a very high TLV.

Indexed as

Fluorine RadioisotopesOligopeptidesPositron Emission Tomography Computed TomographyProstatic NeoplasmsRadiopharmaceuticalsAgedHumansMaleMiddle AgedNeoplasm StagingNiacinamideOrgans at RiskPredictive Value of TestsRetrospective StudiesTissue DistributionTumor BurdenFluorine RadioisotopesNiacinamideOligopeptidesPSMA-1007Radiopharmaceuticals[18F]PSMA−1007PET, tumour sink effectprostate cancerPSMAradioligand therapy

Identifiers

PMID40517368
PMCPMC12167615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.